Corcept Therapeutics Incorporated (CORT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 354 | 366 | 402 | 482 | 675 | 761 | 831 | 1,112 |
| Operating profit | $m | 45 | - | ||||||
| Net profit | $m | 106 | 113 | 101 | 106 | 140 | 100 | 55 | 257 |
| EPS reported | $ | 0.82 | 0.42 | ||||||
| Operating cashflow per share | $ | 1.37 | 1.04 | ||||||
| Capex per share | $ | 0.00 | 0.03 | ||||||
| FCF per share | $ | 1.37 | 1.01 | ||||||
| Free cash flow | $m | 142 | 107 | ||||||
| Net debt | $m | -367 | -308 | ||||||
| Book value equity | $m | 648 | 706 | ||||||
| Book value per share | $ | 5.40 | 5.96 | ||||||
| Number of shares | m | 119.99 | 118.39 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 42.44 | 276.43 | ||||||
| P/B LTM | x | 5.58 | 5.12 | ||||||
| P/S LTM | x | 4.75 | 4.35 | ||||||
| P/FCF LTM | x | 25.49 | 33.80 | ||||||
| EV/EBITDA LTM | x | 51.20 | 121.57 | ||||||
| EV/Sales LTM | x | 4.60 | 14.40 | ||||||
| Earnings Yield LTM | % | +2.36% | +0.36% | ||||||
| FCF Yield | % | +3.92% | +2.96% | ||||||
| Quality | |||||||||
| ROE | % | +15.38% | +8.37% | ||||||
| ROIC | % | +6.67% | +0.87% | ||||||
| Operating margin | % | +5.88% | +0.77% | ||||||
| Gross margin | % | +98.30% | +98.30% | ||||||
| FCF/Sales | % | +18.62% | +12.87% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -33.33% | -65.85% | ||||||
| Sales Growth YoY | % | +12.79% | +23.08% | ||||||
| Net Income Growth YoY | % | -28.68% | -60.71% | ||||||
| FCF Growth | % | -27.62% | -45.42% | ||||||
| Operating Profit Growth | % | -67.29% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 23.22 | 11.35 | ||||||
| Net Debt/EBITDA | x | -1.67 | -3.53 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.14% | +0.08% | ||||||
| Net debt/Equity | x | -0.57 | -0.44 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Corcept Therapeutics Incorporated (CORT)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free